DAVID ALLENBERG contact KATZENSTEIN

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis
    Barbara A Rath
    Department of Pediatrics, Division of Pneumonology Immunology, Charite University Medical Center, Berlin, Germany
    BMC Infect Dis 13:1. 2013
  2. pmc Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study
    Ziad El-Khatib
    Nordic School of Public Health NHV, Gothenburg, Sweden
    BMC Public Health 11:88. 2011
  3. ncbi request reprint Genotype, phenotype, and virtual phenotype: who needs what and why?
    David A Katzenstein
    Stanford University Medical Center, Infectious Disease, S 156, SUMC, Stanford, California 94305 5107, USA
    J Int Assoc Physicians AIDS Care (Chic) 2:140-6. 2003
  4. ncbi request reprint Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa
    David Katzenstein
    Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Infect Dis 194:S45-50. 2006
  5. ncbi request reprint Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine
    Esther J Lee
    Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Infect Dis 192:1260-4. 2005
  6. ncbi request reprint Genetic correlates of efavirenz hypersusceptibility
    Nancy S Shulman
    Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 18:1781-5. 2004
  7. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays
    Nancy S Shulman
    Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
    J Acquir Immune Defic Syndr 39:78-81. 2005
  8. pmc HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes
    Soo Yon Rhee
    Division of Infectious Disease, Stanford University, Stanford, California, USA
    AIDS 20:643-51. 2006
  9. pmc Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis
    Eran Bendavid
    Center for Health Policy and the Center for Primary Care and Outcomes Research, School of Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305, USA
    Arch Intern Med 168:1910-8. 2008
  10. pmc Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis
    Eran Bendavid
    Department of Medicine, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA 94305, USA
    J Acquir Immune Defic Syndr 52:106-13. 2009

Research Grants

  1. Drug Resistance and Pathogenesis in Subtype C HIV-1
    David Katzenstein; Fiscal Year: 2008

Collaborators

Detail Information

Publications36

  1. pmc Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis
    Barbara A Rath
    Department of Pediatrics, Division of Pneumonology Immunology, Charite University Medical Center, Berlin, Germany
    BMC Infect Dis 13:1. 2013
    ..The study was conducted in the first cohort of children gaining access to structured ART in Peru...
  2. pmc Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study
    Ziad El-Khatib
    Nordic School of Public Health NHV, Gothenburg, Sweden
    BMC Public Health 11:88. 2011
    ..We assessed risk factors for incomplete adherence among a cohort of HIV-infected women initiating ART and examined associations between adherence and virologic response to ART...
  3. ncbi request reprint Genotype, phenotype, and virtual phenotype: who needs what and why?
    David A Katzenstein
    Stanford University Medical Center, Infectious Disease, S 156, SUMC, Stanford, California 94305 5107, USA
    J Int Assoc Physicians AIDS Care (Chic) 2:140-6. 2003
  4. ncbi request reprint Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa
    David Katzenstein
    Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Infect Dis 194:S45-50. 2006
    ....
  5. ncbi request reprint Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine
    Esther J Lee
    Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Infect Dis 192:1260-4. 2005
    ..In 20 paired BM and plasma samples, 65% of BM and 50% of plasma RT sequences had NNRTI-resistance mutations, with divergent mutation patterns...
  6. ncbi request reprint Genetic correlates of efavirenz hypersusceptibility
    Nancy S Shulman
    Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 18:1781-5. 2004
    ..NNRTI hypersusceptibility has been associated with improved outcomes to NNRTI-based therapy...
  7. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays
    Nancy S Shulman
    Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
    J Acquir Immune Defic Syndr 39:78-81. 2005
    ..In fact, there was a report that a commercial multicycle assay did not readily detect hypersusceptibility...
  8. pmc HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes
    Soo Yon Rhee
    Division of Infectious Disease, Stanford University, Stanford, California, USA
    AIDS 20:643-51. 2006
    ..As additional non-B sequences from persons with well-characterized antiretroviral treatment histories have become available, the program has been extended to subtypes A, C, D, F, G, CRF01, and CRF02...
  9. pmc Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis
    Eran Bendavid
    Center for Health Policy and the Center for Primary Care and Outcomes Research, School of Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305, USA
    Arch Intern Med 168:1910-8. 2008
    ..Although the number of infected persons receiving highly active antiretroviral therapy (HAART) in low- and middle-income countries has increased dramatically, optimal disease management is not well defined...
  10. pmc Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis
    Eran Bendavid
    Department of Medicine, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA 94305, USA
    J Acquir Immune Defic Syndr 52:106-13. 2009
    ..The effectiveness and cost-effectiveness of increasing the number of antiretroviral regimens is unknown...
  11. ncbi request reprint Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients
    Mark A Winters
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305, USA
    J Infect Dis 188:537-40. 2003
    ..These results show that ddI continues to provide activity against viruses with the M184V/I mutation and suggest that the presence of the M184V/I mutation should not preclude the use of ddI in nucleoside-experienced patients...
  12. pmc High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment
    Elizabeth R Johnston
    Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94035, USA
    J Virol 77:7682-8. 2003
    ..These results suggest that CXCR4-tropic viruses are present within the quasispecies of patients infected with subtype C virus and that antiretroviral treatment may create an environment for the emergence of CXCR4 tropism...
  13. ncbi request reprint Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
    Nancy S Shulman
    Stanford University School of Medicine, California 94305, USA
    J Acquir Immune Defic Syndr 31:121-7. 2002
    ..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
  14. pmc HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy
    Rami Kantor
    Division of Infectious Diseases and AIDS Research, Stanford University, California 94305, USA
    AIDS Res Hum Retroviruses 18:1407-13. 2002
    ..Comparison of subtype C RT and protease sequences with a large database of subtype B sequences identified subtype C-specific polymorphisms and candidate drug resistance mutations...
  15. ncbi request reprint Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs
    David A Katzenstein
    Center for AIDS Research, Stanford, CA, USA
    AIDS 17:821-30. 2003
    ..To evaluate phenotypic drug susceptibility and non-nucleoside reverse transcriptase inhibitor hypersusceptibility as predictors of the time to virological failure...
  16. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
    ..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
  17. ncbi request reprint The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe
    Avinash K Shetty
    Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA
    Int J STD AIDS 16:755-9. 2005
    ..This programme is being implemented at several urban and rural MTCT sites in Zimbabwe and can serve as a model for other resource-poor countries...
  18. ncbi request reprint Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months
    Avinash K Shetty
    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
    J Acquir Immune Defic Syndr 34:482-90. 2003
    ..A phase 3 study is planned to assess the efficacy of OD infant NVP regimen to prevent breast-feeding HIV-1 transmission...
  19. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  20. ncbi request reprint More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175
    Nancy S Shulman
    J Infect Dis 196:328-9; author reply 329-30. 2007
  21. ncbi request reprint Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milk
    Soren Gantt
    Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
    J Infect Dis 196:570-6. 2007
    ..An improved understanding of the relationship between indicators of inflammation and HIV-1 loads in breast milk could improve MTCT prevention strategies...
  22. pmc Cytomegalovirus and Epstein-Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis
    Soren Gantt
    Departments of Pediatrics, Seattle Children s Hospital Research Institute, 1900 Ninth Avenue, Seattle, WA 98101, USA
    AIDS 22:1453-60. 2008
    ..Bacterial infections may cause clinical mastitis, but whether other copathogens common in HIV-1 infection are associated with subclinical mastitis or HIV-1 shedding is unknown...
  23. ncbi request reprint Maternal HIV-1 antibody and vertical transmission in subtype C virus infection
    Hugo Guevara
    Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, CA, U S A
    J Acquir Immune Defic Syndr 29:435-40. 2002
    ..22 and OR = 2.52, respectively. No correlation between NA to homologous HIV-1 subtype C virus and MTCT was found. BA to V3 peptides may provide a rapid inexpensive method that can be used to determine the risk of HIV-1 MTCT...
  24. ncbi request reprint Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB1 in adults coinfected with Mycobacterium tuberculosis in Harare, Zimbabwe
    Lynn S Zijenah
    Department of Immunology, University of Zimbabwe Medical School, Harare, Zimbabwe
    Hum Immunol 63:1026-32. 2002
    ..The observed decreased virus load in HLA-DRB-1 heterozygotes may be due to a better control of M. tb. infection in the context of HIV-1 disease...
  25. ncbi request reprint Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection
    David A Katzenstein
    AIDS Read 18:478-9. 2008
  26. ncbi request reprint Editorial comment: interpretation of resistance tests remains complex
    David A Katzenstein
    AIDS Read 13:141. 2003
  27. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  28. ncbi request reprint Of molecules, macaques and global AIDS
    David A Katzenstein
    AIDS 20:1065-6. 2006
  29. ncbi request reprint Antiretroviral treatment in resource-poor settings: clinical research priorities
    Miriam Rabkin
    Department of Medicine, Columbia University, New York, USA
    Lancet 360:1503-5. 2002
  30. ncbi request reprint Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy
    Camlin Tierney
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 187:144-8. 2003
    ..03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008)...
  31. ncbi request reprint Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years
    Lynn S Zijenah
    Department of Immunology, Division of Infectious Diseases, College of Health Sciences, University of Zimbabwe, Harare
    J Acquir Immune Defic Syndr 39:391-4. 2005
    ..These evaluated parameters were not statistically different between infants aged 0-6 and 7-18 months. The ultrasensitive p24 antigen assay is a useful diagnostic test for detection of HIV-1 infection among infants aged 0-18 months...
  32. ncbi request reprint Editorial comment: resistance testing--an integral part of HIV management
    David A Katzenstein
    AIDS Read 13:36. 2003
  33. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  34. ncbi request reprint Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz
    Ronald J Bosch
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA
    AIDS 17:2395-6. 2003
  35. ncbi request reprint Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels
    David M Simpson
    Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    AIDS 16:407-12. 2002
    ..To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP)...
  36. ncbi request reprint Infant feeding practices of HIV-infected and uninfected women in Zimbabwe
    Danielle Gottlieb
    University of California, San Francisco School of Medicine, San Francisco, California, USA
    AIDS Patient Care STDS 18:45-53. 2004
    ..Knowledge of HIV status may influence infant feeding decisions and reveal an urgent need to address infant feeding practices of pregnant women in Zimbabwe...

Research Grants1

  1. Drug Resistance and Pathogenesis in Subtype C HIV-1
    David Katzenstein; Fiscal Year: 2008
    ..The aim is to study the pathogenesis of subtype C HIV-1 in women and infants after ARV including SD NVP to optimize clinical benefits of ARV treatment and prevention of MTCT. ..